Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Tepotinib is marketed in Australia as Tepmetko.
Tepotinib, sold under the brand name Tepmetko, is an anti-cancer medication used for the treatment of adults with non-small cell lung cancer (NSCLC).
Read the full article on WikipediaStage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) Clinical criteria: Treatment Phase: Initial treatment The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have a WHO performance status of 2 or less, AND Patient must have evidence of MET exon 14 skipping alterations in tumour material.
Tepotinib is marketed in Australia as Tepmetko.
1 brand name is recorded against this substance from the TGA eBS Product Information repository. The full list is in the Also known as card.